Phase I + Phase II Clinical Development Plan for a Novel Fixed-Dose Combination Drug in Erectile Dysfunction Successfully Cleared by the US FDA!
VCRO achieves another critical milestone in US clinical drug development!
With the comprehensive support and strategic planning of VCRO’s expert team, a novel Fixed-Dose Combination (FDC) drug intended for the treatment of erectile dysfunction—pursuing the US 505(b)(2) regulatory pathway—officially received clearance from the US FDA in August 2026 for its Phase I + Phase II clinical development plan, marking its formal entry into US clinical trials.
By leveraging an innovative combination design of existing active pharmaceutical ingredients (APIs), this product is developed as a differentiated therapeutic option with significant market potential. Unlike standard generic drug development (505(j)), the 505(b)(2) pathway places greater emphasis on bridging existing scientific evidence with newly required clinical data. Consequently, a highly integrated development blueprint is critical—spanning product positioning, clinical development strategy, and regulatory interactions with the FDA.
In this project, VCRO supported the client across the end-to-end 505(b)(2) development strategy, FDC clinical pathway planning, Phase I and Phase II trial designs, as well as FDA IND filing and regulatory communications—successfully advancing the novel FDC product from concept to clinical validation.
Securing FDA clearance not only marks a crucial milestone in advancing the product into clinical trials, but also highlights VCRO’s integrated expertise across 505(b)(2) drug development, innovative combination products, early-phase clinical trial design, and US FDA regulatory submissions.
For biopharmaceutical companies seeking to enter the US market through novel combinations, new dosage forms, new routes of administration, or other differentiation strategies, establishing a clear 505(b)(2) regulatory and clinical roadmap early in development is key to maximizing development efficiency and product value.
If you are currently planning a 505(b)(2) new drug, new indication, fixed-dose combination, novel formulation, new route of administration, or other differentiated pharmaceutical project, please visit the VCRO official website to submit an inquiry. Connect with our expert team today to co-create an optimal US clinical and regulatory development strategy tailored to your needs.